Want to see GB:AREC full AI Analyst Report?
AREC Stock Chart & Stats
85.00 p
-0.75 p(-1.01%)
At close: 4:00 PM EST
85.00 p
-0.75 p(-1.01%)
Day’s Range― - ―
52-Week Range55.27 p - 95.00 p
Previous CloseN/A
Volume5.49K
Average Volume (3M)29.41K
Market Cap
£33.41M
Enterprise Value20.50 p
Total Cash (Recent Filing)£6.13M
Total Debt (Recent Filing)£98.00K
Price to Earnings (P/E)41.2
Beta0.44
Next Earnings
Apr 27, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding37,756,600
10 Day Avg. Volume21,861
30 Day Avg. Volume29,408
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)4.71
Price to Sales (P/S)17.73
P/FCF Ratio-12.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.15
Revenue Forecast (FY)£857.00K
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt reduces interest and refinancing pressure, preserving financial flexibility while Arecor advances its development pipeline. This balance-sheet resilience can help the company withstand operating volatility and direct available resources toward formulation programs and partnerships.
Proprietary Formulation PlatformArestat provides a differentiated technology foundation that can be applied across biologic medicines and therapeutic areas. Reusable formulation capabilities may support multiple product programs and improve Arecor’s ability to create licensing opportunities beyond a single asset.
Improved Cash-burn TrajectoryThe substantial reduction in free-cash-flow losses indicates progress in controlling cash consumption, even though the business remains cash negative. If sustained, improved cash discipline could extend funding runway and reduce the urgency of external financing or partnering.
Bears Say
Sharp Revenue ContractionThe 2025 revenue reversal demonstrates that commercial or partnership income remains volatile and difficult to rely on as a steady base. Such a sharp contraction can constrain reinvestment, weaken planning visibility, and make future results more dependent on individual deals or milestones.
Persistent Operating LossesContinued negative EBIT and EBITDA show that Arecor has not yet established self-sustaining operating profitability. Persistent losses can consume equity, limit internally funded development, and increase dependence on successful licensing, milestones, grants, or future capital support.
Ongoing Cash DependenceRecurring negative operating and free cash flow means the business continues to require financing or partnering to support operations and development. This dependence can reduce strategic flexibility and makes execution of commercial agreements important to maintaining financial continuity.
Arecor Therapeutics PLC News
AREC FAQ
What was Arecor Therapeutics PLC’s price range in the past 12 months?
Arecor Therapeutics PLC lowest share price was 55.27 p and its highest was 95.00 p in the past 12 months.
What is Arecor Therapeutics PLC’s market cap?
Arecor Therapeutics PLC’s market cap is £33.41M.
When is Arecor Therapeutics PLC’s upcoming earnings report date?
Arecor Therapeutics PLC’s upcoming earnings report date is Apr 27, 2027 which is in 207 days.
How were Arecor Therapeutics PLC’s earnings last quarter?
Arecor Therapeutics PLC released its earnings results on Sep 30, 2026. The company reported -0.079 p earnings per share for the quarter.
Is Arecor Therapeutics PLC overvalued?
According to Wall Street analysts Arecor Therapeutics PLC’s price is currently Overvalued.
Does Arecor Therapeutics PLC pay dividends?
Arecor Therapeutics PLC does not currently pay dividends.
What is Arecor Therapeutics PLC’s EPS estimate?
Arecor Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arecor Therapeutics PLC have?
Arecor Therapeutics PLC has 37,756,600 shares outstanding.
What happened to Arecor Therapeutics PLC’s price movement after its last earnings report?
Arecor Therapeutics PLC reported an EPS of -0.079 p in its last earnings report. Following the earnings report the stock price went down -18.079%.
Which hedge fund is a major shareholder of Arecor Therapeutics PLC?
Currently, no hedge funds are holding shares in GB:AREC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arecor Therapeutics PLC Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.43%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Arecor Therapeutics PLC
Arecor Therapeutics PLC is a biopharmaceutical enterprise dedicated to creating therapies for diabetes and various other medical conditions. The company utilizes its exclusive Arestat formulation technology platform to both cultivate its own range of specialized products (for diabetes and other ailments) and collaborate with pharmaceutical and biotechnology partners to refine and enhance existing therapeutic formulations. Its pipeline includes AT247, an exceptionally fast-acting insulin aimed at individuals with Type I and Type II diabetes, and AT278, a highly concentrated rapid-acting insulin formulation engineered to hasten insulin absorption following injection. Established in 2007, the company's main office is situated in Little Chesterford, United Kingdom.
Technical Analysis
Avacta Group plc
―
Bioventix
―
Oxford BioMedica
―
Fusion Antibodies Plc
―
Aptamer Group Plc
―